Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 2
1995 1
1996 3
1997 1
1998 2
1999 5
2000 2
2005 6
2006 2
2007 4
2008 4
2009 2
2010 2
2011 5
2012 5
2013 6
2014 5
2015 5
2016 3
2017 2
2018 3
2019 5
2020 12
2021 10
2022 10
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578607 Free article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
[PATIENT-REPORTED OUTCOME AFTER ILEAL NEOBLADDER].
Tomida R, Arai O, Iuchi S, Matsumura M, Hashine K. Tomida R, et al. Among authors: hashine k. Nihon Hinyokika Gakkai Zasshi. 2020;111(4):107-113. doi: 10.5980/jpnjurol.111.107. Nihon Hinyokika Gakkai Zasshi. 2020. PMID: 34670908 Free article. Japanese.
A case of EBV-associated adrenal leiomyoma.
Takemoto T, Kiriyama I, Sugawara Y, Abe C, Teramoto N, Hashine K, Yoshida I, Asagi A. Takemoto T, et al. Among authors: hashine k. Radiol Case Rep. 2024 Mar 16;19(6):2224-2229. doi: 10.1016/j.radcr.2024.02.044. eCollection 2024 Jun. Radiol Case Rep. 2024. PMID: 38523717 Free PMC article.
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: hashine k. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Blas L, et al. Among authors: hashine k. Int J Urol. 2023 Sep;30(9):788-796. doi: 10.1111/iju.15265. Epub 2023 Aug 1. Int J Urol. 2023. PMID: 37528632
102 results